tiprankstipranks
Advertisement
Advertisement

ACAD Stock Latest News

Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
The FlyArm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
11d ago
GM
ARE
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
PremiumThe Fly
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
11d ago
ACAD
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
PremiumThe Fly
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
11d ago
ACAD
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
PremiumCompany Announcements
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
1M ago
8K
ACAD
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
1M ago
ACAD
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
PremiumThe FlyAcadia Pharmaceuticals price target lowered to $29 from $31 at BofA
1M ago
ACAD
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
Premium
Ratings
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
1M ago
ACAD
ACADIA Pharmaceuticals Charts Growth Path After Record Year
Premium
Company Announcements
ACADIA Pharmaceuticals Charts Growth Path After Record Year
1M ago
ACAD
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
1M ago
ACAD
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
1M ago
ACAD
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
1M ago
ACAD
Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
1M ago
ACAD
Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
PremiumThe FlyAcadia Pharmaceuticals price target raised to $35 from $34 at Citizens
1M ago
ACAD
Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
Premium
Ratings
Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
1M ago
ACAD
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
Premium
Ratings
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
1M ago
ACAD
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
PremiumRatings
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
1M ago
ACAD
Acadia Pharmaceuticals reports Q4 EPS $1.60 vs 86c last year
PremiumThe Fly
Acadia Pharmaceuticals reports Q4 EPS $1.60 vs 86c last year
1M ago
ACAD
Acadia Pharmaceuticals sees FY26 revenue $1.22B-$1.28B, consensus $1.2B
PremiumThe Fly
Acadia Pharmaceuticals sees FY26 revenue $1.22B-$1.28B, consensus $1.2B
1M ago
ACAD
Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
PremiumThe Fly
Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
1M ago
ACAD
Acadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
PremiumThe FlyAcadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
1M ago
ACAD
ACAD Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ACAD Upcoming Earnings Report: What to Expect?
1M ago
ACAD
ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch
Premium
Company Announcements
ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch
2M ago
ACAD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >